PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.87%
Revenue growth at 50-75% of ENPH's 19.71%. Martin Whitman would worry about competitiveness or product relevance.
29.38%
Gross profit growth 1.25-1.5x ENPH's 22.33%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
510.02%
EBIT growth above 1.5x ENPH's 44.03%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
150.57%
Operating income growth above 1.5x ENPH's 44.03%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
314.88%
Net income growth above 1.5x ENPH's 49.15%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
316.67%
EPS growth above 1.5x ENPH's 48.15%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
300.00%
Diluted EPS growth above 1.5x ENPH's 46.30%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.10%
Share reduction more than 1.5x ENPH's 1.00%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
10.66%
Diluted share count expanding well above ENPH's 1.56%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
90.53%
Positive OCF growth while ENPH is negative. John Neff would see this as a clear operational advantage vs. the competitor.
68.62%
Positive FCF growth while ENPH is negative. John Neff would see a strong competitive edge in net cash generation.
-49.92%
Negative 10Y revenue/share CAGR while ENPH stands at 195.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-21.54%
Negative 5Y CAGR while ENPH stands at 385.78%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-18.17%
Negative 3Y CAGR while ENPH stands at 199.10%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
88.61%
10Y OCF/share CAGR under 50% of ENPH's 360.60%. Michael Burry would worry about a persistent underperformance in cash creation.
84.07%
Below 50% of ENPH's 5131.94%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
88.00%
3Y OCF/share CAGR under 50% of ENPH's 3115.62%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
290.88%
Net income/share CAGR at 50-75% of ENPH's 465.00%. Martin Whitman might question if the firm’s product or cost base lags behind.
300.31%
Below 50% of ENPH's 1087.67%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
839.36%
3Y net income/share CAGR above 1.5x ENPH's 213.25%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-65.99%
Negative equity/share CAGR over 10 years while ENPH stands at 176.27%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-36.42%
Negative 5Y equity/share growth while ENPH is at 4710.32%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
373.90%
3Y equity/share CAGR above 1.5x ENPH's 239.90%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.10%
AR growth well above ENPH's 17.67%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.57%
Inventory shrinking or stable vs. ENPH's 12.42%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
11.78%
Asset growth 1.25-1.5x ENPH's 10.70%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
35.07%
Similar to ENPH's 33.93%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-5.16%
We’re deleveraging while ENPH stands at 0.19%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-8.39%
Our R&D shrinks while ENPH invests at 12.56%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.36%
We cut SG&A while ENPH invests at 2.31%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.